Leadership Team

Murray Stewart, MD

Murray Stewart, M.D., is Chief Medical Officer at Rhythm Pharmaceuticals, Inc. Previously, he was Executive Vice President, Head of R&D, at Novelion Therapeutics Inc. From April 2014-September 2017, he was the Chief Medical Officer at GlaxoSmithKline. Dr. Stewart joined GSK in 2000 as Associate Director for Clinical Research & Development in the UK and since then has held a variety of positions in GSK he worked in Biopharm, was Therapy Area Head for the Cardiovascular and Metabolic therapy area. He has had extensive clinical development experience and worldwide regulatory interactions. Before joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and was Consultant Physician/Honorary Senior Lecturer and Head of Clinical Services at the Diabetes Centre, Newcastle upon Tyne in the UK. His research was in lipid metabolism in type-2 diabetes, and he completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.

Rebecca Li, PhD

Rebecca Li, PhD, is the CEO of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School.  Previous to her current role she was the Executive Director of the MRCT Center of Brigham and Women’s Hospital and Harvard for over 5 years and remains a Senior Advisor at the Center.  She has over 25 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. She completed a Fellowship in 2013 in the Division of Medical Ethics at Harvard Medical School.  She earned her PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.

Ida Sim, MD, PhD

Ida Sim, MD, PhD is Professor of Medicine at the University of California, San Francisco and co-directs Biomedical Informatics at UCSF’s Clinical and Translational Sciences Institute. Dr. Sim earned her MD and her PhD in Medical Informatics from Stanford University, where her dissertation was on computational methods for data sharing of clinical trial results. She was trained in Primary Care Internal Medicine at the Massachusetts General Hospital, and completed fellowships in General Medicine and Medical Informatics at Stanford.

In 2005-6, Dr. Sim led the World Health Organization’s International Clinical Trials Registry Platform which established the first global policy on clinical trial registration and defined the common 20-item Trial Registration Data Set. She has led multiple NIH and other grants on “trial bank publishing,” ontology-based data sharing of human studies, and clinical trial visualization. Dr. Sim was a member of the 2015 Institute of Medicine committee on “Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk.” She joined the MRCT Clinical Trials Data Sharing project in 2015 and is a co-founder of Vivli.

In other work, Dr. Sim is a national leader in mobile health and co-founder of Open mHealth, a non-profit organization building open APIs and tools for integrating mobile health data. She has served on multiple national advisory committees on health information infrastructure for clinical care and research. She is a recipient of the United States Presidential Early Career Award for Scientists and Engineers (PECASE), a Fellow of the American College of Medical Informatics, and a member of the American Society for Clinical Investigation. She is a practicing clinician.

Julie Wood

Julie Wood is the Chief Operating Officer at Vivli. She is responsible for Operations, including supporting members and researchers with data archiving, access and analysis on the Vivli platform. She is also a Co-Chair of the NIH Generalist Repositories Ecosystem Initiative (GREI) Coopetition Working Group and serves on the Steering Committee of CRDSA. Prior to joining VivliJulie served as the Head of Communications and External Affairs at the Cochrane Collaboration. She has also worked for a Microsoft partner.  

Stan Neumann

Stan Neumann is the Senior Director of Technical Operations at Vivli, where he is responsible for the reliability, usability and functionality of Vivli’s technical platform and supporting members and researchers who use the system. He is also responsible for QA and information and security management.

Prior to joining Vivli, Stan was a project manager and business analyst for BlueMetal Architects, where he helped numerous clients, define a technical vision and then realize that vision through a rigorous application of modern engineering practices and outstanding development skills. Prior to BlueMetal, Stan was the Director of Engineering at Axceler, where he helped the company grow from a startup to one of the most respected creators of SharePoint tools in the industry



Philippa Counter Hogstadius

Philippa serves as the Project Coordinator for Vivli. She holds Master’s Degree in Public Health from Tulane University and a Bachelor’s Degree from Loyola University New Orleans. She studied Political Science for one year at Umeå University in Sweden. Prior to joining Vivli, she worked at Georgetown University School of Medicine in Washington, DC., Planned Parenthood, and The Louisiana Department of Health and Hospitals. She served as a teaching assistant at Tulane University and focused her Public Health Analysis on women’s health disparities in the United States.

Irene Troupansky

Irene Troupansky is the Senior Software Architect at Vivli.

Prior to joining Vivli, Irene was a Senior Software Architect at Examity where she helped the company to launch its first Cloud SaaS Multi-Tenant version of Examity Platform and lead its further design and development through the company rapid growing, insuring Examity’s leading place as online proctoring provider. Prior to Examity, Irene was a Lead Architect/Developer at Tracker Systems, where she helped the company to upgrade its product to a Cloud SaaS version and lead the product further design and development.

Marcia Levenstein

Marcia recently retired as a VP of Statistics at Pfizer with responsibility for clinical development in the CVMET therapeutic area and globally sponsored Pfizer’s China Research & Development Center (CRDC) Statistics organization.  While at Pfizer Marcia led the global biometrics organization for Pfizer’s marketed medicines clinical research programs and established regional biometrics centers for Latin America, Europe, Asia and China. Marcia has extensive experience in the analysis and interpretation of clinical trial data across numerous therapeutic areas, particularly in Cardiovascular and Anti-infectives.  She has served as the statistical leader for regulatory submissions with the responsibility of ensuring biometrics business support of the global pharmaceutical product portfolio. In addition to her role leading Statistics groups, Marcia was a member of Pfizer’s team for the clinical trial disclosure policy, and played a key leadership role in defining Pfizer policy on the issue.  She was a member of Pfizer’s internal steering committee for their Bioethics Advisory Panel and a member of Pfizer’s Clinical Trials Policy Group. She is a member of the Stevens Institute Business Intelligence & Analytics Program Advisory Board, which she joined in 2012. She is a member of the ASA Committee on Professional Ethics. Marcia holds BS degrees in Mathematics and Life Sciences from MIT, an MS in Biostatistics form UNC,  and an ScD in Biostatistics from Harvard University. She received a Masters in Bioethics form U Penn in 2012.

Frank Rockhold

Frank has had diverse research interests and consulting experience in industry and academia including clinical trials design, data monitoring, data standards, benefit/risk, real world evidence, cardiovascular research, and, most recently, safety and pharmacovigilance.  He has been a leader in the scientific community in promoting data disclosure and transparency in clinical research.  Frank is a full-time Professor of Biostatistics and Bioinformatics at Duke Clinical Research Institute.  He is also a Managing Partner of HunterRockhold, Inc., which provides strategic consulting to Industry, Government, and Academia in the areas of clinical trials, pharmacovigilance, data disclosure, and transparency.  Frank’s 40-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he recently retired as Senior Vice President of Global Clinical Safety and Pharmacovigilance.  He has held faculty appointments at six different universities. Frank served for 9 years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials. He is a member of the PCORI Clinical Trials Advisory Panel and is on the board of the Frontier Science and Technology Research Foundation.  Frank is widely published in major scientific journals across a wide variety of research topics. He holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from the Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia. Frank is a Fellow of both the American Statistical Association and the Society for Clinical Trials and an Accredited Professional Statistician, PStat®.